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Abstract
Background: Spinal anesthesia is used as a common anesthetic technique in many routine and outpatient surgeries.
Objectives: The aim of this study was to determine the effect of phenylephrine on maternal hemodynamic changes during spinal
anesthesia for cesarean delivery.
Methods: This double-blind randomized controlled trial was conducted on 116 pregnant women candidate for the elective cesarean
section through spinal anesthesia in the Shahid Akbarabadi Hospital, Tehran in 2019. The eligible women were randomly divided
into the intervention (phenylephrine; n = 58) and control (normal saline; n = 58) groups. The data collection tool was a checklist,
including the demographic and clinical variables, such as age, height, weight, body mass index, gravid, gestational age, Apgar score
of 1 and 5, systolic blood pressure, diastolic blood pressure, heart rate, mean arterial pressure, SPO2, PH of the umbilical cord, PCO2,
HCO3, base excess, nausea, and vomiting. Data were analyzed using SPSS 24 software and P value < 0.05 was considered as significant.
Results: The intervention and control groups showed a significant difference in terms of the PH of the umbilical cord, PCO2, and
nausea and vomiting (P value < 0.05). The results of the repeated measure ANOVA test showed a significant statistical difference
between the intervention and control groups at different time points in terms of arterial pressure, systolic and diastolic blood pres-
sures (P value < 0.05).
Conclusions: Phenylephrine is effective in the prevention of some complications, like reducing mean arterial pressure, systolic and
diastolic blood pressures, nausea, and vomiting during spinal anesthesia for cesarean delivery. Therefore, these drugs can be used
based on maternal hemodynamic status during spinal anesthesia for cesarean delivery.
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1. Background
Spinal anesthesia is used as a common anesthetic tech-
nique in many routine and outpatient surgeries. Today,
given that spinal anesthesia reduces maternal mortality
with no general complications on the mother and new-
borns, it has become the most common anesthetic tech-
nique in cesarean surgery. Studies have shown that ma-
ternal mortality in the cesarean section under spinal anes-
thesia is 16 times less than general anesthesia (1, 2). Spinal
anesthesia causes denervation of the sympathetic, sensory,
and motor nervous system. Also, injection of spinal anes-
thesia solution into the subarachnoid space can interrupt
the conduction in small and non-myelinated strands (sym-
pathetic) prior to dissection of the myelinated and large
fibers (sensory and motor) (3).
However, hypotension is more likely due to the sym-
pathetic block and also the effects of uterine compression
on the aorta and vena cava. Prevention of hypotension is
important to maintain maternal and fetal health. Without
preventive measures, such as fluid therapy, left uterine dis-
placement and Trendelenburg position, hypotension fol-
lowing spinal anesthesia has reported in 80 to 95% of the
patients (4, 5), which may cause nausea, vomiting, dizzi-
ness, decreased level of consciousness, uterine perfusion,
oxygenation of fetus, the increased in risk of aspiration
in the mother, and fetal acidosis. In most cases, despite
preservative measures, a vasopressor, such as phenyle-
phrine or ephedrine is necessary (6, 7). Recent studies have
shown that by administering phenylephrine, a pure alpha-
adrenergic agonist, the mother’s blood pressure is con-
trolled better, nausea, and vomiting are less occurred, and
the risk of fetal acidosis will be lower (8-10).
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2. Objectives
Given the high prevalence of hypotension in spinal
anesthesia during cesarean delivery on the one hand, and
the anesthesiologists’ disagreement on the type of pre-
scribed drug on the other, this clinical trial was designed
and conducted to investigate the effect of infusion of pro-
phylactic phenylephrine on blood pressure, heart rate,
arterial pressure, SPO2, nausea and pregnant mothers’
vomiting during cesarean section under spinal anesthesia.
Also, we aimed at determining the effect of phenylephrine
on the PH of the umbilical cord, PCO2, HCO3, base excess,
and Apgar score of 1 and 5.
3. Methods
3.1. Study Design and Participants
This double-blind randomized controlled trial (RCT)
was conducted on 116 pregnant women candidate for elec-
tive cesarean section under spinal anesthesia in the Shahid
Akbarabadi Hospital, Tehran in 2019. Inclusion criteria in-
cluded pregnant women aged 18 - 45 years, being a can-
didate for cesarean section under spinal anesthesia, ASA 1
and 2 patients, and elective cesarean section. Also, exclu-
sion criteria included a history of allergy to phenylephrine,
body mass index (BMI) > 30 kg/m2, hypertension (> 140/90
mmHg), contraindication for spinal anesthesia, severe car-
diovascular disease, prematurity, emergency cesarean sec-
tion, and inadequate analgesia after spinal anesthesia.
3.2. Data Collection
In the present study, data were collected using a check-
list, including the demographic and clinical characteris-
tics, such as age, height, weight, BMI, gravid, gestational
age, Apgar score of 1 and 5, systolic blood pressure, dias-
tolic blood pressure, heart rate, arterial pressure, SPO2, PH
of the umbilical cord, PCO2, HCO3, base excess, and nausea
and vomiting, based on the collected and recorded inter-
views with patients and clinical examinations.
3.3. Intervention
Prior to the study, the research objectives were ex-
plained to the pregnant subjects and the informed consent
was obtained. Then, the eligible women were divided into
the intervention and control groups (n = 58 per group) us-
ing a random number table. In this double-blind study,
the patients and researchers were blind to group alloca-
tion. The syringe and injection volume were similar in the
placebo.
To perform the intervention, patients were lying in
the supine position with little uterine displacement to the
left on the bed in the operating room. Then, they were
monitored by standard pulse oximetry, non-invasive blood
pressure, and electrocardiogram and their blood pressure,
heart rate, and SPO2 were measured and recorded. In-
travenous administration through a peripheral venous
catheter (18G) was considered and 500 mL of the Ringer
serum received. Then, the intervention group was admin-
istered with 35µg/min of phenylephrine, whereas the con-
trol group was injected with 0.9% normal saline serum.
In both groups, spinal anesthesia was performed with 12
mg of Bupivacaine 0.5% in sitting position using the spinal
needle (G25) at the L3-L4 or L5-L4 intervertebral space. After
anesthesia, to prevent uterine pressure on the aorta and
vena cava, the patient was placed in the supine position
with a little displacement of the uterus to the left. Blood
pressure was measured and recorded every two minutes
until the baby was born. Then, blood pressure, heart rate,
arterial pressure, and SPO2 were monitored continuously
and recorded every two minutes. In the present study,
the patients’ nausea and vomiting were divided into 4 de-
grees: 0 = no, 1 = slight nausea, 2 = nausea requiring treat-
ment, 3 = vomiting. For patients with grade 2 or higher
nausea, 10 mg of the metoclopramide was prescribed.
In both groups, for cases with hypotension of greater
than 20% from the baseline or blood pressure of less than
90 mmHg, 100 µg of the phenylephrine was injected and
this dose was repeated, if needed. Also, atropine 0.01 mg/kg
was prescribed for cases that their heart rate fell below 50
beats per minute. In the intervention group, when the
blood pressure was increased by more than 20% from base-
line, phenylephrine was discontinued, otherwise, it con-
tinued until birth. Also, the PH of the umbilical cord and
the 1-minute and 5-minute Apgar scores were recorded af-
ter birth.
3.4. Statistical Analysis
In the descriptive analysis, mean (SD) and number (%)
were used for quantitative and qualitative variables, re-
spectively. In the analytical analysis, the independent-
samples t-test (existence of normal distribution), Mann-
Whitney U test (lack of normal distribution) and chi-
square test were employed to compare the quantitative
and qualitative variables in two groups. Finally, the re-
peated measures ANOVA test was used to compare the
means of quantitative variables at different time points in
the intervention and control groups. Data were analyzed
using SPSS software (version 24.0) and P value < 0.05 was
considered as significant.
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3.5. Ethical Considerations
The research protocol was in accordance with the prin-
ciples expressed in the Declaration of Helsinki and ap-
proved by the Deputy of Research and Ethics Committee
of Iran University of Medical Sciences (ID-number: 97-3-
58-12859). Additionally, this clinical trial was registered
at the Iranian Registry of Clinical Trials (registration ID:
IR.IUMS.REC.1397.868).
4. Results
The eligible women were randomly divided into two
groups of intervention (n = 58) and control (n = 58) (Fig-
ure 1). Table 1 presents the subjects’ characteristics in the
intervention and control groups at the baseline. Generally,
there was no significant statistical difference between both
groups in terms of age, height, weight, BMI, gravid, and
gestational age at the baseline (P value > 0.05; Table 1).
Table 1. Comparison of the Baseline Variables in the Intervention and Control
Groupsa
Quantitative Variables Values P Value
Age, yb 0.247
Intervention 33.65 ± 4.94
Control 34.48 ± 5.73
Height, cmc 0.997
Intervention 162.40 ± 5.40
Control 159.26 ± 6.28
Weight, kgb 0.756
Intervention 79.56 ± 11.98
Control 79.17 ± 14.20
Body mass index, kg/m2 c 0.203
Intervention 30.07 ± 4.11
Control 31.12 ± 4.59
Gravid, nob 0.433
Intervention 3.04 ± 0.99
Control 3.34 ± 1.40
Gestational age, wkb 0.660
Intervention 37.99 ± 0.73
Control 38.05 ± 0.85
aValues are expressed as mean ± SD.
bMann-Whitney U Test.
cIndependent-samples t-test.
The results of the repeated measures ANOVA test
showed that the values and reduction of the arterial pres-
sure, systolic and diastolic blood pressures in the interven-
tion group were less than the control group at different
time points (Table 2). However, there was no significant dif-
ference between the groups in terms of heart rate and SOP2
at different time periods (Table 2). Also, Figures 2 - 4 show
the variations of these variables at different time points.
In this study, the results of the chi-square test indicated
that the number of nausea requiring treatment and vom-
iting in the intervention group was lower than the con-
trol group (P value < 0.05; Table 3). Also, the results of
the Mann-Whitney U test showed that the mean PH of the
umbilical cord in the intervention group (7.28 ± 0.07) was
higher than the control group (7.21 ± 0.22), however, the
mean PCO2 in the intervention group (50.26 ± 6.43) was
lower than the control group (56.57 ± 10.46; Table 3).
In addition, the results of the chi-square test to com-
pare the used phenylephrine, atropine, and metoclo-
pramide in the intervention and control groups showed
that their rates in the intervention group were lower than
the control group (P value < 0.05). However, there was
no significant statistical difference regarding atropine be-
tween both groups.
5. Discussion
The results of this study were consistent with the find-
ings of other relevant studies. For example, the Ngan Kee
et al. (11) study on the effect of prophylactic phenylephrine
infusion in preventing hypotension during spinal anesthe-
sia for cesarean delivery demonstrated that phenylephrine
infusion was more effective in maintaining the baseline
blood pressure compared with the phenylephrine infu-
sion of 100 µg/min with bolus. In addition, the infusion
group had a reduced incidence of hypotension (23%) com-
pared with the control group (88%). A study by Prakash
et al. (12) showed that 100 µg of phenylephrine or 6 mg
of ephedrine were both effective in treating hypotension
and also the changes of blood pressure were similar in two
studied groups. Another study showed that the infusion
of phenylephrine (100 µg) alone was more effective than
the combination of phenylephrine and ephedrine to con-
trol maternal hemodynamics during spinal anesthesia in
cesarean section (13). It has suggested that phenylephrine
infusion was more beneficial on drug bolus administra-
tion in maintaining patients’ blood pressure during spinal
anesthesia for cesarean delivery (14).
A review by Habib (10) showed that phenylephrine
and ephedrine were both effective in the prevention and
treatment of hypertension following spinal anesthesia
and finally, concluded that the effectiveness of prophy-
lactic infusion of phenylephrine in reducing the inci-
dence of hypotension than bolus administration. How-
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Assessed for Eligibility 
(n = 120) 
Random Allocation = 116 
Phenylephrine Infusion 
(Intervention Group) n = 58 
Analyzed =  58 
Excluded from Analysis (n = 0) 
Analyzed =  58 
Excluded from Analysis (n = 0) 
Normal Saline 
(Control Group) n= 58 
Excluded = 4 
Not Meeting Inclusion Criteria =  3 
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Figure 2. The mean arterial pressure at different time points in the intervention and
control groups
ever, phenylephrine infusion due to its high dose was as-
sociated with a greater reduction in heart rate and sub-
sequently a decrease in cardiac output (10). das Neves et
al. (15) showed that phenylephrine infusion immediately
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Figure 3. The means of systolic blood pressure at different time points in the inter-
vention and control groups
the incidence of hypertension and adverse effects in pa-
tients. Allen et al. (16) demonstrated that the prophylactic
phenylephrine infusion did not reduce the need for inter-
vention by a physician to maintain maternal systolic blood
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Figure 4. The means of diastolic blood pressure at different time points in the inter-
vention and control groups
pressure; however, it decreased the incidence and severity
of hypotension. Finally, they recommended that prophy-
lactic infusion at the doses of 50 and 25 µg/min provided
more hemodynamic stability during spinal anesthesia for
cesarean delivery. Phenylephrine is an alpha-adrenergic
agonist with direct and indirect sympathomimetic effects.
Unlike ephedrine, it has no direct inotropic and chrono-
scopic effects and its administration is associated with re-
flex bradycardia and decreased cardiac output (17). Stud-
ies have shown a dose-dependent reduction in heart rate
following phenylephrine infusion (18). The prophylactic
phenylephrine infusion is associated with a lower heart
rate than treatment with phenylephrine bolus. The inci-
dence of bradycardia in patients receiving phenylephrine
was more than those who received ephedrine (13).
In our study, nausea and vomiting during surgery were
less reported in the phenylephrine group than the control
group, which is consistent with the results of other stud-
ies. For example, George et al. (19) showed that intraop-
erative nausea and vomiting were significantly reduced in
the prophylactic phenylephrine infusion group compared
with the phenylephrine bolus (46% vs. 75%, respectively;
relative risk = 0.61 (95% CI: 0.47 - 0.80)), which was asso-
ciated with the significantly reduced need for antiemetic
drugs in this group. It was lower than the bolus group (26%
vs. 42%; relative risk = 0.62 (95% CI 0.40 to 0.97) (19). In
a study by Atashkhoie et al. (20) on 90 pregnant women
under spinal anesthesia for elective cesarean delivery, nau-
sea and vomiting in the phenylephrine and ephedrine in-
fusion group (intervention group) was significantly lower
than the placebo group.











No 43 (74.10) 20 (34.5)




5 (8.60) 12 (20.70)






Intervention 58 7.28 ± 0.07
Control 58 7.21 ± 0.22
PCO2c 0.001
Intervention 58 50.26 ± 6.43
Control 58 56.57 ± 10.46
Base excessc 0.537
Intervention 58 -2.60 ± 4.70
Control 58 -2.89 ± 2.50
HCO3c 0.056
Intervention 58 23.20 ± 4.07
Control 58 23.93 ± 2.20
Apgar 1c 0.083
Intervention 58 9.00 ± 0.00
Control 58 8.95 ± 0.22
Apgar 5c 0.159
Intervention 58 10.00 ± 0.00
Control 58 9.95 ± 0.29




Phenylephrine is effective in the prevention of some
complications, like reducing mean arterial pressure, sys-
tolic and diastolic pressures, nausea, and vomiting dur-
ing spinal anesthesia for cesarean delivery. These effects
of Phenylephrine make mothers feel better during the
cesarean section and lead to better control of maternal
hemodynamics and ease of operation for the surgeon. In
addition, they are not associated with adverse neonatal
outcomes.
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Table 2. Comparison of the Means of Primary Outcomes in the Intervention and Control Groups at Different Time Points (Repeated Measure ANOVA Test) (N = 58)a
Values P Value
Mean arterial pressure < 0.001b ; < 0.001c ; < 0.001d
T1: Before intervention
Intervention 98.31 ± 7.65
Control 88.72 ± 9.29
T2: 2 minutes after intervention
Intervention 98.83 ± 8.55
Control 84.58 ± 13.77
T3: 4 minutes after intervention
Intervention 90.98 ± 14.27
Control 71.20 ± 15.02
T4: 6 minutes after intervention
Intervention 84.10 ± 14.11
Control 75.52 ± 10.74
T5: 8 minutes after intervention
Intervention 85.65 ± 12.16
Control 78.67 ± 12.84
T6: 10 minutes after intervention
Intervention 83.19 ± 12.36
Control 77.80 ± 9.85
T7: 12 minutes after intervention
Intervention 81.46 ± 10.79
Control 81.33 ± 12.83
Systolic blood pressureb < 0.001b ; < 0.001c ; < 0.001d
T1: Before intervention
Intervention 130.59 ± 8.98
Control 125.74 ± 9.91
T2: 2 minutes after intervention
Intervention 132.69 ± 9.83
Control 114.49 ± 17.31
T3: 4 minutes after intervention
Intervention 125.92 ± 14.31
Control 99.09 ± 15.14
T4: 6 minutes after intervention
Intervention 117.16 ± 17.53
Control 103.53 ± 16.17
T5: 8 minutes after intervention
Intervention 120.16 ± 16.47
Control 111.11 ± 14.88
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T6: 10 minutes after intervention
Intervention 118.04 ± 16.43
Control 115.98 ± 18.70
T7: 12 minutes after intervention
Intervention 118.22 ± 11.42
Control 109.72 ± 13.80
Diastolic blood pressureb < 0.001b ; < 0.001c ; < 0.001d
T1: Before intervention
Intervention 80.63 ± 9.53
Control 76.43 ± 10.28
T2: 2 minutes after intervention
Intervention 81.18 ± 9.15
Control 68.89 ± 13.28
T3: 4 minutes after intervention
Intervention 75.43 ± 12.91
Control 58.45 ± 13.68
T4: 6 minutes after intervention
Intervention 70.47 ± 13.10
Control 61.19 ± 15.52
T5: 8 minutes after intervention
Intervention 70.10 ± 12.44
Control 64.30 ± 12.37
T6: 10 minutes after intervention
Intervention 67.45 ± 12.11
Control 62.72 ± 9.31
T7: 12 minutes after intervention
Intervention 64.59 ± 12.78
Control 63.98 ± 13.51
Heart rateb < 0.001b ; 0.007c ; 0.970d
T1: Before intervention
Intervention 94.33 ± 13.56
Control 89.33 ± 12.16
T2: 2 minutes after intervention
Intervention 96.98 ± 13.92
Control 90.05 ± 15.93
T3: 4 minutes after intervention
Intervention 93.33 ± 15.48
Control 88.51 ± 21.04
T4: 6 minutes after intervention
Intervention 88.50 ± 15.29
Control 81.26 ± 14.25
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T5: 8 minutes after intervention
Intervention 84.65 ± 19.54
Control 77.03 ± 15.92
T6: 10 minutes after intervention
Intervention 82.20 ± 14.35
Control 76.64 ± 15.38
T7: 12 minutes after intervention
Intervention 89.09 ± 13.75
Control 83.31 ± 13.96
aValues are expressed as mean ± SD.
bP value: significant level for time.
cP value: significant level for group.
dP value: significant level for the interaction between group and time.
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